irak4 inhibitor azd2962
Generic: IRAK4 Inhibitor AZD2962
irak4 inhibitor azd2962: 1 clinical trial tracked.
irak4 inhibitor azd2962 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about irak4 inhibitor azd2962, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AZD2962, an IRAK4 Inhibitor, as Monotherapy and in Combination With Other Agents, in Participants With Haematologic Neoplasms
Primary endpoint: Number of participants with dose limiting toxicity (DLT)
Interventionalopen72 targetStarted 2025-11Completion 2028-1021 sites · Australia, Japan, South Korea, Spain…AstraZeneca